Shots:
- F-star is eligible to receive up front and near-term payments of ~$12M & will be eligible for ~$300M as development & sales milestone along with royalties. Payments received by F-star are subject to a CVR agreement in which a portion will be payable to F-star’s investors that were previously stockholders of Spring Bank
- AstraZeneca will obtain the global rights to research, develop & commercialize next-generation STING inhibitor compounds & get exclusive access to F-star’s novel preclinical STING inhibitors
- Additionally, F-star will retain rights to all STING agonists, currently in clinical development for patients with cancer
Click here to read full press release/ article | Ref: GlobeNewswire | Image: PR Newswire
The post AstraZeneca Signs an Exclusive License Agreement with F-star Therapeutics for Novel STING Inhibitors first appeared on PharmaShots.
